TY - JOUR
T1 - Immune function in childhood cancer survivors
T2 - a Children's Oncology Group review
AU - Guilcher, Gregory M.T.
AU - Rivard, Linda
AU - Huang, Jennifer T.
AU - Wright, Nicola A.M.
AU - Anderson, Lynette
AU - Eissa, Hesham
AU - Pelletier, Wendy
AU - Ramachandran, Shanti
AU - Schechter, Tal
AU - Shah, Ami J.
AU - Wong, Ken
AU - Chow, Eric J.
N1 - Funding Information:
GMTG received funding from Jazz Pharmaceuticals to attend the 2017 American Society of Hematology Annual Meeting. All other authors declare no competing interests.
Funding Information:
The Children's Oncology Group is funded by NIH/NCI NCTN Operations Center Grants U10 CA180886, NCTN Statistics and Data Center Grant U10 CA180899, and by NCORP Grant UG1CA189955. EJC receives partial funding as a grantee of the NIH through a Children's Oncology Group subaward. This Review received no direct funding. We would like to acknowledge the guidance and support provided by Melissa Hudson, Wendy Landier, Smita Bhatia, and Louis S Constine.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/4
Y1 - 2021/4
N2 - Childhood cancer and its treatment often impact the haematopoietic and lymphatic systems, with immunological consequences. Immunological assessments are not routinely included in surveillance guidelines for most survivors of childhood cancer, although a robust body of literature describes immunological outcomes, testing recommendations, and revaccination guidelines after allogeneic haematopoietic cell transplantation. Survivorship care providers might not fully consider the impaired recovery of a child's immune system after cancer treatment if the child has not undergone haematopoietic cell transplantation. We did a scoping review to collate the existing literature describing immune function after childhood cancer therapy, including both standard-dose chemotherapy and high-dose chemotherapy with haematopoietic cell rescue. This Review aims to summarise: the principles of immunology and testing of immune function; the body of literature describing immunological outcomes after childhood cancer therapy, with an emphasis on the risk of infection, when is testing indicated, and preventive strategies; and knowledge gaps and opportunities for future research.
AB - Childhood cancer and its treatment often impact the haematopoietic and lymphatic systems, with immunological consequences. Immunological assessments are not routinely included in surveillance guidelines for most survivors of childhood cancer, although a robust body of literature describes immunological outcomes, testing recommendations, and revaccination guidelines after allogeneic haematopoietic cell transplantation. Survivorship care providers might not fully consider the impaired recovery of a child's immune system after cancer treatment if the child has not undergone haematopoietic cell transplantation. We did a scoping review to collate the existing literature describing immune function after childhood cancer therapy, including both standard-dose chemotherapy and high-dose chemotherapy with haematopoietic cell rescue. This Review aims to summarise: the principles of immunology and testing of immune function; the body of literature describing immunological outcomes after childhood cancer therapy, with an emphasis on the risk of infection, when is testing indicated, and preventive strategies; and knowledge gaps and opportunities for future research.
UR - http://www.scopus.com/inward/record.url?scp=85102642258&partnerID=8YFLogxK
U2 - 10.1016/S2352-4642(20)30312-6
DO - 10.1016/S2352-4642(20)30312-6
M3 - Review article
C2 - 33600774
AN - SCOPUS:85102642258
VL - 5
SP - 284
EP - 294
JO - The Lancet Child and Adolescent Health
JF - The Lancet Child and Adolescent Health
SN - 2352-4642
IS - 4
ER -